Clinical trialNCT06395519RecruitingPhase 1/PHASE2Interventional

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Sponsor858 Therapeutics, Inc.Enrollment120Advanced or Metastatic Solid TumorsBRCA MutationBRCA1 MutationBRCA2 MutationBreast CancerCastrate Resistant Prostate Cancer+7 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel McCormick
858 Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic
Phoenix, Arizona, United States
Felipe Batalini, MD
Recruiting
Yale University, Yale Cancer Center
New Haven, Connecticut, United States
Michael Cecchini, MD
Recruiting
Mayo Clinic
Jacksonville, Florida, United States
Pooja Advani, MD
Recruiting
University of Chicago Medical Center
Chicago, Illinois, United States
Han Cun, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Richard T Penson, MD
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Siddhartha Yadav, MD
Recruiting
Laura & Isaac Perlmutter Cancer Center at Nyu Langone Health
New York, New York, United States
Nancy Chan, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Ezra Y Rosen, MD, PhD
Recruiting
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio, United States
Sagar Sardesai, MBBS
Recruiting
Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
Philadelphia, Pennsylvania, United States
Kevin Zarrabi, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Timothy A Yap, MD, PhD
Recruiting
Start Center for Cancer Care - Mountain Region
Salt Lake City, Utah, United States
William B. McKean, Jr, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander I Spira, MD
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Kalyan Banda, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

3-[dideuterio-(1-methylpyrazol-4-yl)methyl]-2-[[(2S)-2-hydroxypropyl]amino]-N-(1-methylcyclopropyl)-4-oxoquinazoline-6-sulfonamide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 May 2024
Primary completion: 31 Dec 2026
Completion: 31 Dec 2026
Last update posted: 27 Mar 2026
Registered enrollment: 120
Registry id: NCT06395519

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.